JPMORGAN CHASE & CO - AKERO THERAPEUTICS INC ownership

AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of AKERO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$36,143,355
+129.5%
714,578
+111.8%
0.00%
+100.0%
Q2 2023$15,749,472
+94.7%
337,320
+59.5%
0.00%
+100.0%
Q1 2023$8,091,000
+80439.5%
211,468
+15.4%
0.00%0.0%
Q4 2022$10,046
-99.9%
183,315
-22.2%
0.00%0.0%
Q3 2022$8,020,000
+261.4%
235,529
+0.3%
0.00%
Q2 2022$2,219,000
+240.9%
234,827
+412.0%
0.00%
Q1 2022$651,000
-35.6%
45,867
-4.1%
0.00%
Q4 2021$1,011,000
-7.3%
47,824
-2.1%
0.00%
Q3 2021$1,091,000
-13.8%
48,830
-4.2%
0.00%
Q2 2021$1,265,000
-9.3%
50,969
+6.1%
0.00%
Q1 2021$1,394,000
+16.1%
48,036
+3.2%
0.00%
Q4 2020$1,201,000
-34.2%
46,545
-20.0%
0.00%
Q3 2020$1,826,000
+15.6%
58,184
-8.3%
0.00%
Q2 2020$1,580,000
+45.5%
63,421
+23.8%
0.00%
Q1 2020$1,086,000
-53.7%
51,249
-51.5%
0.00%
Q4 2019$2,347,000
+22.8%
105,730
+25.9%
0.00%
Q3 2019$1,911,00083,9670.00%
Other shareholders
AKERO THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
ATP Life Science Ventures, L.P. 5,830,203$179,512,00024.20%
venBio Partners LLC 2,444,311$75,260,00011.44%
Versant Venture Management, LLC 777,727$23,946,0004.38%
Redmile Group, LLC 2,336,357$71,936,0001.32%
Vivo Capital, LLC 571,833$17,607,0001.02%
Cormorant Asset Management, LP 859,550$26,466,0001.02%
Boxer Capital, LLC 831,495$25,602,0000.88%
Integral Health Asset Management, LLC 85,000$2,617,0000.80%
EAM Global Investors LLC 49,718$1,531,0000.56%
Crawford Lake Capital Management, LLC 43,826$1,349,0000.56%
View complete list of AKERO THERAPEUTICS INC shareholders